Some “residual uncertainties” in test results acknowledged.
This past week, the U.S. Food and Drug Administration approved Biogen’s new drug, Aduhelm, for treating Alzheimer’s disease, which showed in later test results to help incrementally slow the rate of mental decline in patients by 22%. It is the first new treatment to be approved for the disease since 2003.
“Currently available therapies only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer’s,“ said Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research. “As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research and innovation.”
As the Lord Leads, Pray with Us…
- For the FDA as they seek to give Americans access to treatment options. they deserve.
- For U.S. scientists as they research and assess medications and therapies.
- For Dr. Cavazzoni as she handles further drug evaluations in her new role.
- For those suffering from Alzheimer’s and the loved ones caring for them.
Sources: AP, FDA.gov
